Showing posts with label Cetrorelix. Show all posts
Showing posts with label Cetrorelix. Show all posts

Friday, December 21, 2012

Cetrorelix at the ACR 2012 in Washington



Cetrorelix is a gonadotropin-releasing hormone antagonist (GnRH antagonist). I expected some new results. Older results here: http://rheumatologe.blogspot.de/2012/07/cetrorelix-at-eular-2012.html

And there are new results! A. Kass and colleagues looked at cetrorelix in a proof-of concept study and it demonstrates efficacy in patients with active rheumatoid arthritis (Abstract No. 834). Their results showed that “more patients on cetrorelix achieved ACR20 responses (40% vs 18%; p_0.015)”. Nothing that makes drop off your chair, but at least a result to work on. Conclusions included: “Larger, long-term studies on the efficacy and safety of GnRH antagonists in RA patients are warranted.”

No other abstract on cetrorelix! It doesn’t sound like a success story, but it’s interesting enough to be followed. We’ll just have to wait for further results.
19.06.2013
Nothing at the EULAR 2013 Meeting in Madrid.

Thursday, July 19, 2012

Cetrorelix at the EULAR 2012



Cetrorelix is a gonadotropin-releasing hormone antagonist (GnRH antagonist). At the EULAR 2012 meeting in Berlin there has been one study.
A. Kåss an colleagues aimed in this proof-of-concept study at whether cetrorelix can reduce TNF-α in RA patients, improve signs and symtoms, and to investigate safety. The study ran for 5 days on cetrorelix with examinations also at day 10 and 15. Reduction of TNF-alpha has been significant as compared to placebo. DAS-28 didn't reach statistical significance. ACR20 did, however.


[OP0202] CETRORELIX, A GONADOTROPIN-RELEASING HORMONE ANTAGONIST, SIGNIFICANTLY REDUCES TNF-ALPHA AND DEMONSTRATES EFFICACY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: A PROOF-OF-CONCEPT, DOUBLE-BLIND RANDOMISED TRIAL
A. Kåss1,2, H.C. Gulseth1, I. Hollan2,3, M. Fagerland4, P. Torjesen5, Ø. Førre6. 1Dept. of Rheumatology, Betanien Hospital, Skien; 2University of Oslo, Oslo; 3Dept. of Rheumatology, Lillehammer Hospital, Lillehammer; 4Dept. of Biostatistics and Epidemiology; 5Hormone Laboratory; 6Dept. of Rheumatology, Oslo University Hospital, Oslo, Norway
Conclusions: This study demonstrates antagonising GnRH with cetrorelix lowers TNF-α, and improves signs and symptoms of RA. This study suggests that clinically relevant interactions between GnRH and the immune system exist; which may improve insights into the pathogenesis of RA. Larger, long-term studies on the efficacy and safety of GnRH antagonists in RA patients are warranted.


Two important things! One, the study medication has only been given for five days. Shall we see better effects or more adverse events if it's given daily for a longer time. Two, cetrorelix significantly suppresses testosterone levels … Per aspera ad astra!